健脾通络方治疗恶性肿瘤相关睡眠障碍的临床疗效研究

注册号:

Registration number:

ITMCTR2024000213

最近更新日期:

Date of Last Refreshed on:

2024-08-11

注册时间:

Date of Registration:

2024-08-11

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

健脾通络方治疗恶性肿瘤相关睡眠障碍的临床疗效研究

Public title:

Clinical efficacy of spleen spleen in treatment of sleep disorders associated with malignant tumor

注册题目简写:

English Acronym:

研究课题的正式科学名称:

健脾通络方治疗恶性肿瘤相关睡眠障碍的临床疗效研究

Scientific title:

Clinical efficacy of spleen spleen in treatment of sleep disorders associated with malignant tumor

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

周霖

研究负责人:

任建琳

Applicant:

Lin Zhou

Study leader:

Jianlin Ren

申请注册联系人电话:

Applicant telephone:

+86 173 1758 3329

研究负责人电话:

Study leader's telephone:

+86 187 0983 9422

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zhoulin8666@163.com

研究负责人电子邮件:

Study leader's E-mail:

renjianlin666@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市静安区芷江中路274号

研究负责人通讯地址:

上海市静安区芷江中路274号

Applicant address:

No. 274 Zhijiang Middle Road, Jing'an District, Shanghai

Study leader's address:

No. 274 Zhijiang Middle Road, Jing'an District, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

200071

研究负责人邮政编码:

Study leader's postcode:

200071

申请人所在单位:

上海市中医医院

Applicant's institution:

Shanghai Traditional Chinese Medicine Hospital

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2024SHL-KY-01-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

上海市中医医院伦理委员会

Name of the ethic committee:

Ethics Committee of Shanghai Traditional Chinese Medicine Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024/2/7 0:00:00

伦理委员会联系人:

凌丽

Contact Name of the ethic committee:

Li Lin

伦理委员会联系地址:

上海市静安区芷江中路274号上海市中医医院

Contact Address of the ethic committee:

Shanghai Traditional Chinese Medicine Hospital, No. 274 Zhijiang Middle Road, Jing'an District, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 121 5662 8310

伦理委员会联系人邮箱:

Contact email of the ethic committee:

shszyyyec@126.com

研究实施负责(组长)单位:

上海市中医医院

Primary sponsor:

Shanghai Traditional Chinese Medicine Hospital

研究实施负责(组长)单位地址:

上海市静安区芷江中路274号上海市中医医院

Primary sponsor's address:

Shanghai Traditional Chinese Medicine Hospital, No. 274 Zhijiang Middle Road, Jing'an District, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

静安区

Country:

China

Province:

Shanghai

City:

Jing an district

单位(医院):

上海市中医医院

具体地址:

上海市静安区芷江中路274号

Institution
hospital:

Shanghai Traditional Chinese Medicine Hospital

Address:

Shanghai Traditional Chinese Medicine Hospital, No. 274 Zhijiang Middle Road, Jing'an District, Shanghai

经费或物资来源:

国家自然科学基金( 82174452、81873279),上海市科委项目(19401935200、22S21901000),上海申康医院临床三年行动计划疑难攻关项目(HDC2020CR2047B),上海医学创新发展基金会中医药传承项目(WLJH2021ZY-MZY026),上海中医药大学预算内项目(18LK057)

Source(s) of funding:

National Natural Science Foundation of China (82174452, 81873279), Shanghai Municipal Science and Technology Commission project (19401935200, 22S21901000), Shanghai Shenkang Hospital Clinical Three Year Action Plan Difficulty Solving Project (HDC200CR2047B), Shanghai Medical Innovation and Development Foundation Traditional Chinese Medicine Inheritance Project (WLJH2021ZY-MZY026), Shanghai University of Traditional Chinese Medicine Budget Project

研究疾病:

恶性肿瘤相关睡眠障碍

研究疾病代码:

Target disease:

Malignancy tumor-associated sleep disorders

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

通过随机双盲对照研究,评估健脾通络方治疗恶性肿瘤相关睡眠障碍的临床疗效及安全性。

Objectives of Study:

To evaluate the clinical efficacy and safety of spleen and lung prescription in a randomized double-blind controlled study.

药物成份或治疗方案详述:

治疗组: 入组后接受健脾通络颗粒治疗1个月: 1)脾虚证:健脾通络颗粒:生黄芪30 g、苦参15 g、党参15 g、炒白术15 g、白茯苓15 g、炒薏苡仁15 g、白花蛇舌草30 g、天龙3 g、蜈蚣3 g、甘草6 g。 对照组: 入组后接受健脾通络安慰剂颗粒治疗1个月,安慰剂与治疗组等量、气味外观均相同的安慰剂颗粒,含10%治疗组药物。 所有颗粒药物均为江阴天江药业有限公司提供,每日一剂,分早晚两次服用,口服用药,80℃左右温开水400ml溶解中药颗粒,分成2份,分两次温服。

Description for medicine or protocol of treatment in detail:

Treatment Group: After enrollment, they were treated with Jianpi Tongluo granules for 1 month: 1) Spleen deficiency syndrome: spleen tongluo granules: 30 g, 15 g, 15 g, 15 g, 15 g, 15 g, 15 g, 15 g, 30 g, 3 g, Tianlong 3 g, centipede 3 g, licorice 6 g. Control group: After enrollment, they received 1 month of placebo particles with the same amount and odor appearance, containing 10% treatment group. All granule drugs were provided by Jiangyin Tianjiang Pharmaceutical Co., LTD., with one dose a day, twice in the morning and evening. Oral medication, 400ml of 80℃ warm water, divided into two parts and taken in two times.

纳入标准:

1)符合上述诊断标准诊断为恶性肿瘤; 2)符合肿瘤相关睡眠障碍诊断标准; 3)符合中医脾虚证 4)年龄≥18岁,性别不限; 5)预计生存期≥6个月的患者,体力状况评分标准(ECOG)≤2; 6)同意接受随访; 7)随访及临床相关病历资料完整; 8)自愿签署知情同意书者。

Inclusion criteria

1)Diagnosis as malignant tumor meets the above diagnostic criteria; 2)Meet the diagnostic criteria for tumor-related sleep disorders; 3) In line with the TCM spleen deficiency syndrome 4) Age is 18 years old, and gender is unlimited; 5)Patients with an estimated survival period of 6 months, physical strength status scoring criteria (ECOG) 2; 6)Consent to receive the follow-up visit; 7)Complete follow-up and clinical relevant medical records; 8)To voluntarily sign the informed consent form.

排除标准:

1)合并严重心、脑、肝、肾疾病、电解质异常或精神病者; 2)对本研究所用药物或其成分过敏者; 3)妊娠期、哺乳期或计划妊娠患者; 4)存在严重或难以控制的感染; 5)近2周内服用其他中药者或参加其它临床试验者。

Exclusion criteria:

1)Patients with severe heart, brain, liver and kidney diseases, electrolyte abnormalities or mental illness; 2) Allto drugs or ingredients used in the study; 3)Pregnancy, lactation, or planned pregnancy patients; 4) presence of severe or uncontrollable infection; 5)Those who took other Chinese medicine or participated in other clinical trials.

研究实施时间:

Study execute time:

From 2024-02-07

To      2024-08-16

征募观察对象时间:

Recruiting time:

From 2024-02-10

To      2024-06-30

干预措施:

Interventions:

组别:

治疗组

样本量:

60

Group:

Treatment group

Sample size:

干预措施:

入组后接受健脾通络颗粒治疗1个月: 1)脾虚证:健脾通络颗粒:生黄芪30 g、苦参15 g、党参15 g、炒白术15 g、白茯苓15 g、炒薏苡仁15 g、白花蛇舌草30 g、天龙3 g、蜈蚣3 g、甘草6 g。

干预措施代码:

Intervention:

After enrollment, they were treated with Jianpi Tongluo granules for 1 month: 1) Spleen deficiency syndrome: spleen tongluo granules: 30 g, 15 g, 15 g, 15 g, 15 g, 15 g, 15 g, 15 g, 30 g, 3 g, Tianlong 3 g, centipede 3 g, licorice 6 g.

Intervention code:

组别:

对照组

样本量:

60

Group:

control group

Sample size:

干预措施:

入组后接受健脾通络安慰剂颗粒治疗1个月,安慰剂与治疗组等量、气味外观均相同的安慰剂颗粒,含10%治疗组药物。 所有颗粒药物均为江阴天江药业有限公司提供,每日一剂,分早晚两次服用,口服用药,80℃左右温开水400ml溶解中药颗粒,分成2份,分两次温服。

干预措施代码:

Intervention:

After enrollment, they received 1 month of placebo particles with the same amount and odor appearance, containing 10% treatment group. All granule drugs were provided by Jiangyin Tianjiang Pharmaceutical Co., LTD., one dose a day, taken twice in the morning and evening. Oral medication, 400ml of 80℃ warm water, divided into two parts and taken in two times.

Intervention code:

样本总量 Total sample size : 120

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海

市(区县):

静安区

Country:

china

Province:

Shanghai

City:

Jing An district

单位(医院):

上海市中医医院

单位级别:

上海市中医医院

Institution/hospital:

Shanghai Traditional Chinese Medicine Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

匹兹堡睡眠质量指数PSQI量表评分

指标类型:

主要指标

Outcome:

The Pittsburgh Sleep Quality Index PSQI scale score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量测评表

指标类型:

次要指标

Outcome:

QLQ-CR38

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肿瘤指标

指标类型:

次要指标

Outcome:

CEA CA199 CA50 CA125 AFP

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

卡氏评分

指标类型:

次要指标

Outcome:

KPS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医证候积分

指标类型:

次要指标

Outcome:

Traditional Chinese Medicine Syndrome Points

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

bleed

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

结束

Completed

年龄范围:

最小 18
Min age years
最大 85
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用两级盲法设计,第一级为各病例号所对应的组别(如A组或B组),第二级为各组所对应的处理(试验组或对照组)。随机编码表由第三方人员建立,两级盲底分别单独密封,各一式二份,分别存放于研究人员及第三方人员处。

Randomization Procedure (please state who generates the random number sequence and by what method):

Using a two-stage blind design, the first level is the corresponding group of each case number (e. g., Group A or Group B), and the second level is the treatment corresponding to each group (test group or control group). The random code table is established by a third party, and the two-level blind bases are sealed separately and stored in duplicate with the researcher and the third party respectively.

盲法:

采用两级盲法设计,第一级为各病例号所对应的组别(如A组或B组),第二级为各组所对应的处理(试验组或对照组)。随机编码表由第三方人员建立,两级盲底分别单独密封,各一式二份,分别存放于研究人员及第三方人员处。当病例报告表全部录入后,数据被锁定后进行第一次揭盲(即明确A组、B组),之后交由统计学专业人员统计分析。当统计分析结束后进行第二次揭盲,明确试验组和对照组。

Blinding:

Using a two-stage blind design, the first level is the corresponding group of each case number (e. g., Group A or Group B), and the second level is the treatment corresponding to each group (test group or control group). The random code table is established by a third party, and the two-level blind bases are sealed separately in duplicate with the researcher and the third party respectively.When all the case report forms are entered, the data are locked for the first unblinding (i. e., clear A group, B group), and then submitted to statistical professionals for statistical analysis. When the statistical analysis was completed, the test group and the control group were identified.

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2025.5.30 ResMan(www.medresman.org.cn)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

2025.5.30 ResMan(www.medresman.org.cn)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表(Case Record Form, CRF)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

暂无

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

None

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统